T
Thomas F. Gamage
Researcher at Research Triangle Park
Publications - 29
Citations - 847
Thomas F. Gamage is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Cannabinoid & Cannabinoid receptor. The author has an hindex of 15, co-authored 25 publications receiving 702 citations. Previous affiliations of Thomas F. Gamage include Temple University & Virginia Commonwealth University.
Papers
More filters
Journal ArticleDOI
Role of α5 Nicotinic Acetylcholine Receptors in Pharmacological and Behavioral Effects of Nicotine in Mice
Kia J. Jackson,Michael J. Marks,Robert E. Vann,Xiangning Chen,Thomas F. Gamage,Jonathan A. Warner,M. I. Damaj +6 more
TL;DR: Results show that α5(−/−) mice are less sensitive to the initial effects of nicotine in antinociception, locomotor activity, and hypothermia measures and that the α5 nAChR is involved in nicotine reward.
Journal ArticleDOI
Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol
Robert E. Vann,Thomas F. Gamage,Jonathan A. Warner,Ericka M. Marshall,Nathan L. Taylor,Billy R. Martin,Jenny L. Wiley +6 more
TL;DR: CBD, when administered with THC at therapeutically relevant ratios, may ameliorate aversive effects often associated with initial use of THC alone, and this effect may be beneficial for therapeutic usage of a CBD:THC combination medication.
Journal ArticleDOI
Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Thomas F. Gamage,Charlotte E. Farquhar,Timothy W. Lefever,Julie A. Marusich,Richard C. Kevin,Iain S. McGregor,Jenny L. Wiley,Brian F. Thomas +7 more
TL;DR: This study demonstrates that novel structures being sold and used illicitly as substitutes for cannabis are retaining high affinity at the CB1 receptor, exhibiting greater efficacy than THC, and producing THC-like effects in models relevant to subjective effects in humans.
Journal ArticleDOI
Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
Divya Ramesh,Thomas F. Gamage,Tim Vanuytsel,Tim Vanuytsel,Robert A. Owens,Rehab A. Abdullah,Micah J. Niphakis,Terez Shea-Donohue,Benjamin F. Cravatt,Aron H. Lichtman,Aron H. Lichtman +10 more
TL;DR: These results are the first to show that endocannabinoid catabolic enzyme inhibitors reduce abrupt withdrawal in morpine-dependent mice and are effective in a novel in vitro model of opioid withdrawal.
Journal ArticleDOI
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569
Thomas F. Gamage,Bogna M. Ignatowska-Jankowska,Jenny L. Wiley,Mostafa H. Abdelrahman,Laurent Trembleau,Iain R. Greig,Ganesh A. Thakur,Ritesh B. Tichkule,Justin L. Poklis,Ruth A. Ross,Roger G. Pertwee,Aron H. Lichtman +11 more
TL;DR: The utility of Org27569 as a ‘gold standard’ CB1AM is questioned and the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal is underscored.